A new approach to the treatment of invasive pneumococcal diseases (360G-Wellcome-089325_Z_09_C)

£437,952

Streptococcus pneumoniae causes a very high number of cases of pneumonia, meningitis and bacteraemia, worldwide. Despite using antibiotics that kill the bacterium, a large number of patients still die and in meningitis, many survivors have profound neurological handicap. This is because the bacterium produces a very damaging virulence factor that is not inhibited by antibiotics. This problem constitutes an unmet medical need that Professor Peter Andrew and colleagues from the University of Leicester are proposing to fulfill. They have identified that small molecules can inhibit this virulence factor and are effective in vivo. The team have been awarded funding through the Seeding Drug Discovery initiative to identify new small molecules and through a programme of medicinal chemistry, combined with in vitro and in vivo testing, to identify lead compounds with appropriate efficacy, pharmacokinetics and toxicology. The aim is that giving such molecules will reduce the number of patients that die or suffer handicap as a result.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 437952
Applicant Surname Andrew
Approval Committee Seeding Drug Discovery Committee
Award Date 2012-07-16T00:00:00+00:00
Financial Year 2011/12
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 089325/Z/09/C
Lead Applicant Prof Peter Andrew
Partnership Value 437952
Planned Dates: End Date 2013-03-26T00:00:00+00:00
Planned Dates: Start Date 2011-11-27T00:00:00+00:00
Recipient Org: Country United Kingdom
Region East Midlands